GHK-Cu's skincare receipts, the longevity-injection detour, and where the evidence actually ends

The Cold Open

GHK-Cu has quietly become the most respectable peptide on the market. It shows up in serums at Sephora, in compounded wound-care gels, and in anti-aging clinics charging four figures for an injection series. The skincare evidence is surprisingly solid. The injection story is not. This month: where the research supports the hype, and where the hype keeps walking past the research.

Peptide of the Month: GHK-Cu

What it is. GHK is a tiny three-amino-acid peptide (glycine, histidine, lysine) that was pulled from human blood plasma in 1973. It binds copper readily, and the resulting GHK-Cu complex is what most products sell. Think of GHK as a copper-delivery shuttle: it carries copper into skin and connective tissue, where copper is a cofactor in collagen production, wound repair, and extracellular matrix remodeling.

What it's supposedly for. Topical skincare (wrinkles, elasticity, photoaging), wound healing (especially in diabetic foot ulcers), hair growth, and more recently, injectable "longevity" protocols at peptide clinics.

The evidence as of today. Here the story splits in two. For topical use, the evidence is legitimately encouraging: a 1994 randomized trial in diabetic foot ulcers showed GHK-Cu gel outperformed standard care, a 2016 double-blind trial found wrinkle depth improvements over eight weeks, and several smaller studies back up collagen-related effects. For injectable "systemic longevity" use, the evidence stops cold. No controlled human trial has evaluated GHK-Cu injections for aging, hair growth, or whole-body rejuvenation.

One thing to know: topical works. The strongest clinical signal for GHK-Cu lives at the skin's surface. If someone recommends it, that's where the research backs them up. The deeper the claim goes into the body, the thinner the evidence gets.

GHK-Cu is one of the few peptides where the skincare receipts are better than the longevity receipts.

The catch. GHK-Cu is not FDA-approved as a drug, though it's widely used in cosmetic formulations. The main problems are claim inflation and delivery format. Peptide clinics sometimes pitch injectable GHK-Cu as an organ-regenerating longevity therapy, which is not supported by any human trial. And copper dosing matters: too much copper in tissue isn't neutral, it's pro-oxidative. Topical serums deliver small, controlled doses to skin. Injections do not have the same margin of error.

Myth Check: "Injectable GHK-Cu is a longevity therapy"

Walk into enough clinics and you'll hear it: GHK-Cu injections reverse aging, regenerate organs, restart tissue repair pathways that slow with age. The pitch often cites review papers describing broad gene-expression changes in lab cell cultures.

The gap: lab-dish observations and controlled human outcomes are not the same thing. The gene-expression data is interesting and real. It just doesn't demonstrate what the clinics are selling. A 2018 review by the peptide's original discoverer summarizes the preclinical signals clearly, and then notes that controlled human longevity outcomes have not been established.

So what: GHK-Cu is a genuinely useful peptide, but its genuine usefulness lives in topical skincare and wound healing, not systemic injection. When a clinic reaches for the injectable longevity pitch, they are reaching past the evidence.